Rare brain cancer treatment now affordable via PBS subsidy

A rare brain cancer that strikes people in their prime now has its first targeted treatment in two decades, and as of August 1st, Australian patients can access it through the government's subsidized medicines scheme. The drug, vorasidenib, sold under the brand name Voranigo, works by slowing the progression of IDH-mutant astrocytoma and oligodendroglioma—slow-growing tumors caused by a specific genetic mutation. Before the listing, the monthly cost was $28,000. Now it's affordable to anyone with a prescription.

The disease itself is unforgiving. It causes seizures, cognitive decline, physical disability, and progressive loss of independence. Most people diagnosed are in their twenties and thirties—young enough to have decades of life ahead, old enough to have built lives that the illness systematically dismantles. Health Minister Mark Butler described it bluntly: the condition "hits people in very young adulthood, usually in their 20s and 30s, and is deeply, deeply debilitating." Around 135 Australians receive this diagnosis each year.

For decades, doctors had only blunt instruments: surgery to remove what they could reach, radiation, chemotherapy. The addition of vorasidenib to the PBS marks a genuine shift in what clinicians can offer. Jim Whittle, a medical oncologist at Peter McCallum Cancer Centre, framed it as expanding the toolkit—another option to discuss with patients, another way to fight back against a disease that has historically offered little hope.

Leah Ferguson, a 38-year-old from Victoria, embodies what this shift means in practice. She was diagnosed two and a half years ago, just months after giving birth to her daughter Lulu. Surgeons removed most of her tumor but had to leave a small section untouched in a part of her brain too delicate to operate on. She started taking Voranigo two years ago. The drug hasn't cured her—there is no cure—but it has given her something she describes as precious: the ability to stop thinking about her remaining tumor every single day. "The main thing I wanted was more time with my daughter," she said. "I can have this quality of time and just think about doing the fun things, living with Lulu and my family."

That framing matters. This is not a story about miraculous recovery. It's a story about what happens when a person with an incurable illness gets a tool that lets them live differently—not constantly braced for the next seizure, the next cognitive slip, the next loss of function. It's about the difference between enduring a disease and managing it. For Ferguson, it meant trading daily dread for something closer to ordinary life with her young daughter.

The PBS listing also addresses a brutal practical reality: before August 1st, only patients who could afford $28,000 a month could access this treatment. That price tag excluded most people. Now, through the government subsidy, the drug is within reach for anyone whose doctor prescribes it. The expansion of access to other medicines on the same August listing—two Crohn's disease treatments now available to children, reducing costs from $500 to $25 per prescription—suggests a broader policy shift toward making newer, more targeted therapies available to Australians who need them.

What remains unknown is how long vorasidenib will hold the line against these tumors, and for whom it will work best. The drug slows progression; it doesn't stop it. Patients and their doctors will be watching closely to see how much extra time it buys, and whether that time remains good time—functional, independent, livable. For now, though, there is something that wasn't there before: a real option, an actual tool, a reason to hope that the next appointment might bring good news instead of bad.